To include your compound in the COVID-19 Resource Center, submit it here.

April 30 Clinical Quick Takes: Xencor, Axovant, Cell Medica

Partial hold lifted on Xencor's blood cancer bispecific
FDA lifted a partial clinical hold on a Phase I trial of XmAb14045 from Xencor

Read the full 228 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE